Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068789743> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2068789743 endingPage "863" @default.
- W2068789743 startingPage "858" @default.
- W2068789743 abstract "Thirty-one adult patients with adenocarcinoma of the lung were treated with FCC chemotherapy consisting of 5-fluorouracil (5-FU), cyclophosphamide, and CCNU every 4 weeks. Thirteen patients received 5-FU orally (POF) at the dose of 400 mg/m2/day in 4 divided daily doses for 5 days, whereas 18 patients received 5-FU at the dose of 800 mg/m2/day for 5 days as a continuous intravenous infusion (CIF). All patients received cyclophosphamide and CCNU orally at doses of 200 mg/m2/day for 4 days and 40 mg/m2/day for 2 days, respectively. The overall response was 22%. Response was greater in patients treated with FCC-CIF (4/14 vs. 1/9; p = 0.6), in patients with limited disease (4/13 vs. 1/10; p = 0.5), and in patients with good performance status, (4/16 vs. 1/7). The overall median survival duration was 9 months. The patients who achieved tumor regression survived significantly longer than patients who had disease stabilization (median, 21 vs. 9 months; p = 0.01), and the latter survived significantly longer than patients who had progressive disease (median, 9 vs. 2.5 months; p = 0.003). There was no significant difference in survival duration in the two FCC-treated groups. Pretreatment extent of disease and performance status did not influence the survival of patients. However, the FCC-CIF-treated group contained a greater number of patients with extensive disease and poor performance status. Further investigations are indicated to evaluate the efficacy of 5-fluorouracil administered by continuous intravenous infusion in combination with cyclophosphamide and CCNU in bronchogenic carcinoma." @default.
- W2068789743 created "2016-06-24" @default.
- W2068789743 creator A5032585930 @default.
- W2068789743 creator A5047189073 @default.
- W2068789743 creator A5060563693 @default.
- W2068789743 creator A5072786200 @default.
- W2068789743 creator A5078169692 @default.
- W2068789743 creator A5082916862 @default.
- W2068789743 date "1979-09-01" @default.
- W2068789743 modified "2023-09-26" @default.
- W2068789743 title "Chemotherapy for adenocarcinoma of the lung with 5-fluorouracil, cyclophosphamide, and CCNU (FCC)" @default.
- W2068789743 cites W1986645531 @default.
- W2068789743 cites W1988310302 @default.
- W2068789743 cites W1994769053 @default.
- W2068789743 cites W2010599756 @default.
- W2068789743 cites W2030175426 @default.
- W2068789743 cites W2047227363 @default.
- W2068789743 cites W2058003419 @default.
- W2068789743 cites W2076205522 @default.
- W2068789743 cites W2135069339 @default.
- W2068789743 cites W2143594378 @default.
- W2068789743 cites W2394852390 @default.
- W2068789743 cites W4253007472 @default.
- W2068789743 cites W4293241248 @default.
- W2068789743 cites W4323966495 @default.
- W2068789743 doi "https://doi.org/10.1002/1097-0142(197909)44:3<858::aid-cncr2820440310>3.0.co;2-p" @default.
- W2068789743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/476597" @default.
- W2068789743 hasPublicationYear "1979" @default.
- W2068789743 type Work @default.
- W2068789743 sameAs 2068789743 @default.
- W2068789743 citedByCount "5" @default.
- W2068789743 crossrefType "journal-article" @default.
- W2068789743 hasAuthorship W2068789743A5032585930 @default.
- W2068789743 hasAuthorship W2068789743A5047189073 @default.
- W2068789743 hasAuthorship W2068789743A5060563693 @default.
- W2068789743 hasAuthorship W2068789743A5072786200 @default.
- W2068789743 hasAuthorship W2068789743A5078169692 @default.
- W2068789743 hasAuthorship W2068789743A5082916862 @default.
- W2068789743 hasConcept C121608353 @default.
- W2068789743 hasConcept C126322002 @default.
- W2068789743 hasConcept C141071460 @default.
- W2068789743 hasConcept C2776694085 @default.
- W2068789743 hasConcept C2776755627 @default.
- W2068789743 hasConcept C2776907518 @default.
- W2068789743 hasConcept C2778822529 @default.
- W2068789743 hasConcept C2779563347 @default.
- W2068789743 hasConcept C2780456651 @default.
- W2068789743 hasConcept C2781182431 @default.
- W2068789743 hasConcept C71924100 @default.
- W2068789743 hasConcept C90924648 @default.
- W2068789743 hasConceptScore W2068789743C121608353 @default.
- W2068789743 hasConceptScore W2068789743C126322002 @default.
- W2068789743 hasConceptScore W2068789743C141071460 @default.
- W2068789743 hasConceptScore W2068789743C2776694085 @default.
- W2068789743 hasConceptScore W2068789743C2776755627 @default.
- W2068789743 hasConceptScore W2068789743C2776907518 @default.
- W2068789743 hasConceptScore W2068789743C2778822529 @default.
- W2068789743 hasConceptScore W2068789743C2779563347 @default.
- W2068789743 hasConceptScore W2068789743C2780456651 @default.
- W2068789743 hasConceptScore W2068789743C2781182431 @default.
- W2068789743 hasConceptScore W2068789743C71924100 @default.
- W2068789743 hasConceptScore W2068789743C90924648 @default.
- W2068789743 hasIssue "3" @default.
- W2068789743 hasLocation W20687897431 @default.
- W2068789743 hasLocation W20687897432 @default.
- W2068789743 hasOpenAccess W2068789743 @default.
- W2068789743 hasPrimaryLocation W20687897431 @default.
- W2068789743 hasRelatedWork W1989798994 @default.
- W2068789743 hasRelatedWork W1993729317 @default.
- W2068789743 hasRelatedWork W2029856305 @default.
- W2068789743 hasRelatedWork W2045344299 @default.
- W2068789743 hasRelatedWork W2058479958 @default.
- W2068789743 hasRelatedWork W2062900024 @default.
- W2068789743 hasRelatedWork W2092942708 @default.
- W2068789743 hasRelatedWork W2147292731 @default.
- W2068789743 hasRelatedWork W2407744598 @default.
- W2068789743 hasRelatedWork W2498109984 @default.
- W2068789743 hasVolume "44" @default.
- W2068789743 isParatext "false" @default.
- W2068789743 isRetracted "false" @default.
- W2068789743 magId "2068789743" @default.
- W2068789743 workType "article" @default.